This is Part 2 of a company deep dive on Novo Nordisk $NVO which includes an analysis of its balance sheet, cash flow, earnings forecasts and my valuations.

Currently trading close to +3SD above its five-year forward mean PE, the share price seems overbought and may be due for a mean reversion in the near term.

What do you think? Does it still have legs?

Read it here: https://intvestor.substack.com/p/novo-nordisk-as-part-2-declining